Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC
Summit Therapeutics (US:SMMT) Businesswire·2026-01-12 19:00公司动态 - 公司Summit Therapeutics Inc (NASDAQ: SMMT) 已向美国食品药品监督管理局 (FDA) 提交了生物制品许可申请 (BLA) [1] - 该BLA旨在寻求批准其新型、首创的双特异性抗体ivonescimab联合化疗用于治疗特定患者群体 [1] - 目标适应症为表皮生长因子受体 (EGFR) 突变的局部晚期或转移性非鳞状非小细胞肺癌的二线或更晚治疗 [1]